

SAFEGUARD SCIENTIFICS INC

Form 8-K

May 26, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported) **May 26, 2009**

**Safeguard Scientifics, Inc.**

(Exact Name of Registrant as Specified in Charter)

<b>Pennsylvania</b>	<b>1-5620</b>	<b>23-1609753</b>
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification
<b>435 Devon Park Drive, Building 800, Wayne, PA</b>	<b>19087</b>	
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code **610-293-0600**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**ITEM 8.01. Other Events**

On May 14, 2009, Clariant, Inc. (“Clariant”), then a majority-owned subsidiary of Safeguard Scientifics, Inc. (the “Company”), completed the second closing under that certain Stock Purchase Agreement between Clariant and Oak Investment Partners XII, Limited Partnership. Upon the second closing, the Company’s ownership of Clariant’s issued and outstanding voting securities, on an as-converted basis, decreased from 50.2% to 47.3%. As a result of such sale of securities by Clariant, the Company deconsolidated its holdings in Clariant as of that date since it no longer holds a controlling financial interest in Clariant. There is no cash flow impact as a result of such deconsolidation.

In the quarter ending June 30, 2009, the Company expects to recognize an unrealized gain in income from continuing operations as a result of the deconsolidation in the amount of approximately \$120 million, resulting in a corresponding increase in the Company’s shareholders’ equity. The entire amount of the gain relates to the remeasurement to fair value of the Company’s retained interest in Clariant as of May 14, 2009. The Company has elected to apply the fair-value option to account for its retained interest in Clariant; therefore, unrealized gains and losses on the mark-to-market of its holdings in Clariant will be recognized in income from continuing operations in subsequent periods.

**ITEM 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release dated May 26, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Safeguard Scientifics, Inc.

Dated: May 26, 2009 By: BRIAN J. SISKO  
Brian J. Sisko  
Senior Vice President and General Counsel